TY - JOUR
T1 - New technologies in clinical microbiology
AU - Wolk, Donna M.
AU - Dunne, W. Michael
PY - 2011/9
Y1 - 2011/9
N2 - Rapid identification of microorganisms in the clinical microbiology laboratory can be of great value for selection of optimal patient management strategies for infections caused by bacteria, viruses, fungi, mycobacteria, and parasites. Rapid identification of microorganisms in clinical samples enables expedient de-escalation from broad-spectrum agents to targeted antimicrobial therapy. The switch to tailored therapy minimizes risks of antibiotics, namely, disruption of normal flora, toxic side effects, and selective pressure. There is a critical need for new technologies in clinical microbiology, particularly for bloodstream infections, in which associated mortality is among the highest of all infections. Just as importantly, there is a need for the clinical laboratory community to embrace the practices of evidence-based interventional laboratory medicine and collaborate in translational research projects to establish the clinical utility, cost benefit, and impact of new technologies.
AB - Rapid identification of microorganisms in the clinical microbiology laboratory can be of great value for selection of optimal patient management strategies for infections caused by bacteria, viruses, fungi, mycobacteria, and parasites. Rapid identification of microorganisms in clinical samples enables expedient de-escalation from broad-spectrum agents to targeted antimicrobial therapy. The switch to tailored therapy minimizes risks of antibiotics, namely, disruption of normal flora, toxic side effects, and selective pressure. There is a critical need for new technologies in clinical microbiology, particularly for bloodstream infections, in which associated mortality is among the highest of all infections. Just as importantly, there is a need for the clinical laboratory community to embrace the practices of evidence-based interventional laboratory medicine and collaborate in translational research projects to establish the clinical utility, cost benefit, and impact of new technologies.
UR - https://www.scopus.com/pages/publications/80053213047
UR - https://www.scopus.com/pages/publications/80053213047#tab=citedBy
U2 - 10.1128/JCM.00834-11
DO - 10.1128/JCM.00834-11
M3 - Article
AN - SCOPUS:80053213047
SN - 0095-1137
VL - 49
SP - S62-S67
JO - Journal of clinical microbiology
JF - Journal of clinical microbiology
IS - 9 SUPPL.
ER -